While human epidermal growth factor receptor 2 (HER2) aberrations have long been
described in patients with non-small cell lung cancer (NSCLC), they have only recently been …

Epidermal growth factor receptor 2 (HER2/ErbB2/neu), a member of ErbB receptor tyrosine
kinase family, forms homo-or heterodimers with ErbB1 (HER1/EGFR), ErbB3 (HER3), or …

Oncogenic driver mutations identified in non-small cell lung cancer (NSCLC) have triggered
the development of drugs capable of interfering in intracellular signaling pathways involved …

HER2 mutations, which account for 2–4% of non-small cell lung cancer (NSCLC), are
distinct molecular alterations identified via next generation sequencing (NGS). Previously …

Simple Summary There are growing data on targeting HER2 alterations, which include gene
mutations, gene amplifications, and protein overexpression, for non-small cell lung cancer …

Over the last two decades HER2 aberrations have been thoroughly investigated as potential
therapeutic targets in advanced non–small cell lung cancer, with relatively modest results …

PURPOSE HER2 is a critical gene that drives various solid tumors in addition to those of
breast cancer. For example, HER2 plays a role in non–small-cell lung cancer (NSCLC) …

Lung cancer stands as the first cause of death by cancer in the world. Despite the
improvement in patients' outcomes in the past decades through the development of …

Oncogenic driver mutations have emerged as major treatment targets for molecular
therapies in a variety of cancers. HER2 positivity has been well-studied in breast cancer, but …

e20666 Background: We have previously shown that human epidermal growth factor
receptor 2 (HER2, ERBB2) mutation and amplification represent distinct molecular entities in …